Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study
Tessa Therapeutics today announced enrollment of 12 patient Pilot cohort of its Phase 2 trial…
Continue Reading
-
-
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue Reading -
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading -
Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer
Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over…
Continue Reading -
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma
Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from…
Continue Reading -
Tessa Therapeutics Announces New Executive Leadership
Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…
Continue Reading -
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…
Continue Reading -
Interview Series | In Pursuit of A Cancer Cure: Conversations with Immunotherapy Advocates – Dr Ramy Ibrahim, CMO at PICI
Our CSO, Dr John Connolly, discusses the next decade of cellular immunotherapy breakthroughs with Dr…
Continue Reading -
Interview Series | In Pursuit Of Cancer Cure: Conversations With Immunotherapy Advocates – Dr Jonathan Maltzman
In this latest interview, Dr Jonathan Maltzman discusses the potential of harnessing Regulatory T Cells…
Continue Reading -
Industry Perspectives from Tessa Therapeutics Board Member, Dr Göran Ando, on the Potential of Cell Therapy
Dr Göran Ando, who joined Tessa’s Board of Directors last April, recently visited our Corporate…
Continue Reading